iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025

NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, March 19, 2025.

Earnings call details are as follows:

Toll Free: 877-545-0523
International: 973-528-0016
Participant Access Code: 174549
Webcast: https://www.webcaster4.com/Webcast/Page/2879/52064

About iCAD, Inc.

iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com.

Forward-Looking Statements

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.


CONTACTS

Media inquiries:

[email protected]

Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
[email protected]



Enphase Energy Launches Next-Generation IQ EV Charger across Europe

FREMONT, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced production shipments of its newest electric vehicle (EV) charger, the IQ® EV Charger 2, in 14 European markets. The IQ EV Charger 2 is a smart charger designed to work seamlessly with Enphase solar and battery systems or as a powerful standalone charger. With advanced energy management features, the charger empowers homeowners to maximize solar self-consumption, lower energy costs, and enjoy a smart, efficient EV charging experience.

The IQ EV Charger 2 is now available in Norway, Germany, the United Kingdom (UK), France, the Netherlands, Sweden, Denmark, Switzerland, Austria, Belgium, Luxembourg, Italy, Spain, and Portugal. The charger’s top features include:

  • Charge with solar: The IQ EV Charger 2 intelligently prioritizes surplus solar energy for EV charging, maximizing clean energy use. With automatic phase switching between three-phase and single-phase modes, it can begin charging with as little as 1.38 kW of solar production — helping homeowners reduce electricity costs and increase sustainability.
  • AI Optimization: Powered by advanced forecasting algorithms and real-time electricity rate data, the charger intelligently selects the most economical energy source — solar, battery, or grid.
  • Built-in intelligence: Smart capabilities include goal-based charging, dynamic load balancing, and a certified MID energy meter for accurate energy tracking and reimbursement — ideal for home and fleet applications.
  • Future-ready bidirectional charging: The IQ EV Charger 2 is equipped with built-in hardware and software to support AC bidirectional charging. While availability depends on EV compatibility, standards, and regional certifications, this feature is designed to enable vehicle-to-home (V2H) and vehicle-to-grid (V2G) integration — empowering homeowners with resilience and flexibility.

“As EV adoption continues to rise, consumers are seeking intelligent solutions for efficient home charging without driving up energy costs,” said Wesley van den Enk, director at Hydro Solar B.V., an installer of Enphase products in the Netherlands. “Enphase’s new IQ EV Charger not only optimizes cost savings across all tariffs but also integrates seamlessly with Enphase home energy systems, empowering homeowners to maximize solar for EV charging and minimize their carbon footprint.”

The IQ EV Charger 2 is designed for high performance and long-term reliability. Available in both socketed and tethered variants, it features a rugged Type-2 connector that is fully compatible with the majority of EVs sold in Europe. With configurable power levels up to 32 A per phase, the charger supports both single-phase and three-phase wiring from the same hardware — simplifying logistics and reducing inventory complexity. Installation is fast and efficient, featuring a 7.5-meter cable for added flexibility and a streamlined, sub-10-minute setup process that minimizes labor time and installation cost.

The IQ EV Charger 2 is housed in an IP55-rated enclosure, making it weatherproof and safe for both indoor and outdoor installations. Engineered to the highest standards, the charger is safety certified by TÜV Rheinland, with MID certification by NMI, and includes additional market-specific certifications to meet regional compliance requirements. All chargers activated in select European countries come backed by an industry-leading five-year warranty and 24/7 customer support from Enphase — ensuring long-term reliability and exceptional peace of mind.

“We’re excited to begin rolling out the new IQ EV Charger to our customers,” said Mickaël Garcia, general manager of NRJ Ingénierie, an installer of Enphase products in France. “The integration with the Enphase App will allow homeowners to manage their energy use and vehicle charging around the clock, ensuring their vehicles are ready to go when they need them.”

“Consumers are looking for efficient home charging solutions as EV adoption increases,” said Theo Schmalbruch at Theo Tec GmbH, an installer of Enphase products in Germany. “The new IQ EV Charger from Enphase comes at a time when customizable power options are a high priority for homeowners. With this EV charger, our customers can manage their energy consumption and ensure their vehicles are charged when they need them.”

“We’re thrilled to expand our total home energy management solutions with our IQ EV Charger 2 across Europe, creating a comprehensive offering for both installers and homeowners,” said Jayant Somani, senior vice president of the digital business unit at Enphase Energy. “By choosing Enphase, homeowners can have confidence they’re investing in top-quality, innovative products designed to meet their energy needs.”

To learn more about Enphase’s IQ EV Charger 2 in Europe, visit the websites for Norway, Germany, UK, France, the Netherlands, Sweden, Denmark, Switzerland (German, French, Italian), Austria, Belgium (French, Dutch), Luxembourg, Italy, Spain, and Portugal.

About Enphase Energy, Inc.

Enphase Energy, a global energy technology company based in Fremont, CA, is the world’s leading supplier of microinverter-based solar and battery systems that enable people to harness the sun to make, use, save, and sell their own power — and control it all with a smart mobile app. The company revolutionized the solar industry with its microinverter-based technology and builds all-in-one solar, battery, and software solutions. Enphase has shipped approximately 80.0 million microinverters, and approximately 4.7 million Enphase-based systems have been deployed in more than 160 countries. For more information, visit https://enphase.com/.

©2025 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. in the U.S. and other countries. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy’s technology and products, including safety, quality, and reliability; expectations regarding the payback period for solar homeowners throughout Europe; expectations regarding lifetime savings to customers; and statements regarding the timing and availability Enphase Energy’s products in Europe. These forward-looking statements are based on Enphase Energy’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties including those risks described in more detail in Enphase Energy’s most recently filed Annual Report on Form 10-K, and other documents filed by Enphase Energy from time to time with the SEC. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

Contact:

Enphase Energy

[email protected]

This press release was published by a CLEAR® Verified individual.



Annovis Joins Experts at Drug Development Summit to Redefine Parkinson’s Treatment

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), will participate at the 13th Alzheimer’s & Parkinson’s Drug Development Summit happening on March 18-20 in Boston, MA.

“This meeting represents an important opportunity to advance our understanding of the next-generation treatment for neurodegenerative diseases, which we have long argued are too complex for a narrow therapeutic approach. Research must shift to a more holistic solution, addressing multiple neurotoxic proteins and moving beyond the limited focus of targeting just one, which has hindered the progress in the field,” says Maria Maccecchini, Ph.D., Founder and CEO of Annovis. “We will present the lessons learned from our AD and PD clinical trials, delve into buntanetap’s mechanism of targeting alpha-synuclein, and discuss ways to usher in a new era for Parkinson’s treatment.”

Annovis will give a presentation and participate in a panel discussion, both taking place on March 19:

Presentation: Highlighting Phase III Buntanetap Data & Embracing a More Holistic Approach to Neurodegenerative Disease Targeting

  • Time: 3:30pm EST
  • Presenter: Maria Maccecchini, Ph.D., Founder and CEO

Panel Discussion: Exploring Opportunities in Alpha-Synuclein & Beyond for More Transformative & Efficacious Therapies: What’s Coming Next in Parkinson’s Drug Development?

  • Time: 4:30pm EST
  • Participant from Annovis: Maria Maccecchini, Ph.D., Founder and CEO

The 13th Alzheimer’s & Parkinson’s Drug Development Summit is the only industry-focused, end-to-end meeting that provides comprehensive coverage from early discovery to late-stage development focused on deciphering the complexity of neurodegenerative diseases in pursuit of novel therapeutic targets.

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:

Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:

Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
[email protected]



Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

  • Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic
  • Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerability
  • OV350, Ovid’s first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025
  • Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of 2026

NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.

“Ovid is at an exciting inflection point. Our pipeline programs are moving into the next stage of clinical development and I believe our team is the strongest that it has been since the founding of the Company,” said Dr. Jeremy Levin, D.Phil., MB BChir., Chairman and CEO of Ovid Therapeutics. “To support us in capturing the substantial potential therapeutic and financial value associated with OV329, our program for treatment-resistant epilepsies, and our portfolio of first-in-class KCC2 activators, Dr. Stelios Papadopoulos has joined our Board and two industry leaders, Dr. Manal Morsy and Victoria “Tori” Fort joined our management team. Stelios’s extensive industry expertise and strategic vision will be invaluable to Ovid through our next stage of growth. Manal and Tori will support our regulatory and investor strategy and engagement,” stated Levin.

Business Strategy & Updates

Ovid expects its cash runway to support operations and clinical development programs into the second half of 2026, during which time multiple pipeline and regulatory milestones are anticipated. These anticipated milestones include: results for OV329 biomarker and safety data (Q3 2025); initiation of a Phase 2a patient study for OV329 in drug resistant epilepsies (Q1 2026); results from a first-in-human safety and exploratory biomarker study with OV350, our first KCC2 direct activator (Q4 2025); and initiation of human trials for the first oral KCC2 direct activator, OV4071 (Q2 2026). In the event the Company is unable to raise capital or enter into partnerships or co-development opportunities as and when needed, it will be required to delay, reduce the scope of or prioritize various research and development activities.

The Company will continue to manage its clinical development programs, operations and cash expenditures with fiscal discipline to support the potential achievement of key value-creating clinical milestones. Given the breadth and depth of its pipeline, and the broad therapeutic opportunity it may yield, Ovid will continue to explore partnerships and co-development opportunities for select programs and regions to accelerate development and offset costs. Additional pipeline updates follow below.

Organizational Updates

Ovid has strengthened its Board of Directors and leadership team with key appointments intended to support the Company’s pipeline, business development and financial strategies. These include:

  • Appointed Stelios Papadopolous, Ph.D., to serve on Board of Directors. Dr. Papadopolous is a scientist, investor and entrepreneur who has played a pivotal role in shaping the biotechnology industry for the last 30 years through bridging scientific discovery with financial strategy. His leadership, deal-making creativity, and ability to catalyze growth will be instrumental to Ovid as it seeks to capture the full potential value of its pipeline programs. Dr. Papadopoulos has served in roles including: the Vice Chairman of Cowen & Co., LLC; a leader in investment banking at PaineWebber, Chairman of PaineWebber Development Corp., a subsidiary focusing on biotechnology; and Vice President in the Equity Research Department of Drexel Burnham Lambert, covering the biotechnology industry. Dr. Papadopolous will serve on the Audit and Compensation Committees of Ovid’s Board of Directors.
  • Leadership appointments. In February 2025, Manal Morsy, M.D., Ph.D., MBA and Victoria Fort joined Ovid as Chief Regulatory Officer and Head of Corporate Affairs & Corporate Strategy, respectively. Dr. Morsy brings deep expertise from successful global regulatory strategies and submissions spanning three decades, including adult and pediatric development drug candidates at J&J, Merck, PTC, and Athersys. She is a trained scientist, clinician and geneticist whose work has been published in many leading scientific and medical journals. Ms. Fort joins Ovid from Frontier Medicines, where she led corporate strategy, guided the company’s transition to a clinical-stage organization and helped secure critical financing.

Pipeline Strategy & Updates

Ovid is advancing a differentiated pipeline of potential first-in-class and best-in-class small molecule medicines that are intended to bring hyperexcited neurons back to homeostasis. The Company seeks to become a leader in neurotherapeutics by addressing intractable brain disorders with significant unmet need. This includes treating conditions and symptoms that manifest from excessive neural excitation such as seizures and psychosis.

Central to the Company’s strategy is identifying and developing differentiated mechanisms of action to interdict unaddressed biological targets in the central nervous system (CNS) that are fundamental to disease pathology. This strategy includes developing a potential best-in-class, next-generation GABA aminotransferase (GABA-AT) inhibitor; translating the direct activation of the potassium chloride co-transporter 2 (KCC2) for a broad range of neurological and psychiatric conditions; and pioneering Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibition for neurovascular and neuro-inflammatory conditions.


OV329

  • A next-generation GABA-AT inhibitor: Ovid is developing OV329 as a next-generation GABA-AT inhibitor for the potential treatment of drug-resistant epilepsies (DREs) in adult and pediatric patients. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. Ovid’s preclinical characterization suggests that OV329 is 100-fold more potent than vigabatrin in animals, delivers synaptic and extra-synaptic inhibition, and has a lasting pharmacodynamic effect despite rapid tissue clearance. In animal models, OV329 has been shown to have a therapeutic index and does not appear to induce sedation at therapeutic doses, whereas vigabatrin has no therapeutic window. A therapeutic dose of vigabatrin has been shown by independent researchers, and by Ovid, to preferentially accumulate in the retina.
  • Human safety & tolerability: Ovid is completing a Phase 1 single- ascending dose (SAD) and multiple ascending dose (MAD) study evaluating OV329’s safety, tolerability, pharmacokinetics (PK) and biomarkers that may serve as a measure of clinical effect and target engagement. In the cohorts completed to-date, there have been no serious adverse events and no adverse events reported have been associated with OV329.
  • Topline biomarker & safety data expected Q3 2025: Ovid added a higher dose cohort to its Phase 1 study, to increase dosing opportunities for future Phase 2 programs. Topline results from this cohort is expected in Q3 2025, and will include findings regarding how OV329 performed in specific parameters of transcranial magnetic stimulation (TMS) and magnetic resonance spectroscopy (MRS). Collectively, Ovid believes TMS and MRS have the potential to detect GABAergic activity, target engagement and clinical effect.

    • TMS is a proven protocol for focal non-invasive electrical cortical stimulation that can safely and non-invasively measure target engagement. TMS has been previously used to correlate anti-seizure activity with vigabatrin and other anti-seizure medications (“ASMs”). Ovid is utilizing a range of TMS parameters for OV329, which can measure cortical excitation, including GABA-ergic, GABA (A) and GABA (B) receptor activity1.
    • MRS technology has been utilized with other ASMs, including vigabatrin, as a way to measure GABA levels in selected regions of the brain. Utilizing MRS, Ovid will be able to evaluate and quantify the change in GABA levels in the medial parietal lobe relative to an untreated baseline.
  • Ocular safety profile: To evaluate OV329’s safety compared to vigabatrin, Ovid has conducted additional animal experiments to evaluate the risk of drug accumulating in the eye and causing retinal cell dysregulation. At the 2024 American Epilepsy Society meeting in December, Ovid presented the full results from an animal study, which demonstrated that OV329 did not accumulate in animal eyes, in contrast to vigabatrin, which was found to accumulate in less than 48 hours. OV329 was present in the brain and plasma of mice, then rapidly cleared the tissue and remained undetectable in the retina, eye, and brain. In contrast, vigabatrin was demonstrated to preferentially accumulate in the eye, retina and brain, which is consistent with previously published independent research.


OV350 and KCC2 library

  • Initiated a Phase 1, first-in-human study for a KCC2 direct activator, OV350: In Q4 2024, Ovid successfully submitted a regulatory application for a Phase 1 trial of OV350 and initiated a first-in-human study for this class of molecule in Q1 2025. OV350 is the first of multiple anticipated programs from Ovid’s library of KCC2 direct activators. The Phase 1 trial intends to evaluate the safety, tolerability and pharmacokinetic parameters of an intravenous formulation of OV350 in healthy human volunteers. It will also include an exploratory biomarker using quantitative EEG. In preclinical and animal disease models, OV350 has demonstrated antipsychotic and anticonvulsant effects, indicating that it may have broad therapeutic utility. The initial indication intended for OV350, and the oral program to follow, is psychosis associated with neuronal-synuclein diseases (NSD), including Parkinson’s disease, and Lewy body dementia (LBD). These conditions have similar underlying biology, significant unmet need and an established regulatory pathway.
  • KCC2 direct activator library. Ovid has made significant progress with its KCC2 direct activator library and is progressing four programs toward clinical development, which are expected to yield successive regulatory submissions annually for the next three to four years. These programs are unique structures with discreet pharmacology and differentiated therapeutic attributes as characterized in phenotypic and disease biology models. Ovid believes these molecules may have relevance across a range of conditions that have symptoms driven by neural hyperexcitability such as seizures and psychoses. Based upon the bioavailability and potency characteristics, Ovid believes different programs in the library have amenability for oral and intramuscular or subcutaneous formulations to address clinical indications across the care continuum.
  • OV4071, the first oral KCC2 direct activator: Ovid has initiated IND-enabling studies of OV4071, the first oral direct activator of the biological target, KCC2. It anticipates initiating human studies with OV4071 in Q2 2026, with both healthy volunteer and patient cohorts. This oral program behaves similarly to OV350 in phenotypic and disease model screens and is similarly intended for the potential treatment of psychoses in NSD and LBD.


OV888/GV101 & ROCK2 inhibitor programs

  • OV888/GV101 Capsule for CCM: In the third quarter of 2024, Ovid and Graviton Bioscience announced the decision to pause the initiation of the Phase 2 proof-of-concept study of OV888/ GV101 capsule, following the recent completion of long-duration competitor and academic trials in CCM, and after discussions with key stakeholders. Ovid and Graviton Bioscience are evaluating clinical design learnings and regulatory feedback from recently completed competitor Phase 2 programs. Ovid and Graviton Bioscience are confident of the potential therapeutic effects of ROCK2 inhibition for CCM and will seek to optimize future development approaches with the benefit of further insights on study duration, enrichment strategies, endpoints, and time-to-event measurements.

Fourth
Quarter and Annual
2024
F
inancial Results

  • Cash, cash equivalents and marketable securities as of December 31, 2024 totaled $53.1 million.
  • Revenues from royalty agreements were $566,000 for the year ended December 31, 2024, as compared to $392,000 for the same period in 2023.
  • Research and development expenses were $5.9 million and $36.8 million for the three months and full year ended December 31, 2024, compared to $10.6 million and $28.6 million for the same periods in 2023. The overall increase is related to the advancement of Ovid’s clinical and preclinical pipeline programs as described above. The decrease between the three-month periods is the result of the organizational restructuring in the second quarter of 2024, which re-prioritized development programs.
  • General and administrative expenses were $4.9 million and $25.7 million for the three months and full year ended December 31, 2024, as compared to $7.7 million and $31.1 million for the same periods in 2023. The decrease was driven by the previous organizational restructuring and related cost-reduction efforts.
  • Total operating expenses were $10.8 million and $62.5 million for the three months and full year ended December 31, 2024, as compared to $18.3 million and $59.7 million for the same periods in 2023.
  • Ovid reported a net loss of $9.3 million, or basic and diluted net loss per share attributable to common stockholders of $0.13 for the three months ended December 31, 2024, as compared to a net loss of $15.3 million, or basic and diluted net loss per share attributable to common stockholders of $0.21 for the same period in 2023. Ovid reported a net loss of $26.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.37 for the year ended December 31, 2024, as compared to a net loss of $52.3 million, or basic and diluted net loss per share attributable to common stockholders of $0.73 for the same period in 2023.

1 Tsuboyama M, Lee Kaye H, Rotenberg A. Biomarkers Obtained by Transcranial Magnetic Stimulation of the Motor Cortex in Epilepsy.
Front Integr Neurosci. 2019 Oct 30;13:57. doi: 10.3389/fnint.2019.00057. PMID: 31736722; PMCID: PMC6837164.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, highly specific, small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple neurological and psychiatric conditions; and OV888/GV101, a highly selective ROCK2 inhibitor for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Forward-Looking Statements

This press release includes certain disclosures by Ovid that contain “forward-looking statements” including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid’s clinical studies; Ovid’s expectations regarding the duration of its cash runway and the expectation that it will support Ovid’s operations and development programs; Ovid’s ability to achieve expected benefits of cost-savings efforts; Ovid’s ability to secure additional sources of funding; Ovid’s potential future business development opportunities; the potential use and development of OV329, OV350 and other compounds from Ovid’s library of direct activators of KCC2, and OV888/GV101; the potential therapeutic opportunity of OV329, OV350 and other compounds from Ovid’s library of direct activators of KCC2, and OV888/GV101; Ovid’s evaluation of the results of recently completed competitor trials to OV888/GV101 for CCM; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, impediments to Ovid’s ability to achieve expected benefits of cost-savings efforts, risks related to Ovid’s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy, or risks related to Ovid’s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Condensed Consolidated Statements of Operations

Unaudited

(in thousands, except share and per share data) For the Three Months Ended
December 31, 2024
  For the Three Months Ended
December 31, 2023
  For the Year Ended
December 31, 2024
  For the Year Ended
December 31, 2023
Revenue:              
License and other revenue $ 76     $ 142     $ 566     $ 392  
Total revenue   76       142       566       392  
Operating expenses:                  
Research and development   5,923       10,642       36,767       28,588  
General and administrative   4,878       7,688       25,684       31,085  
Total operating expenses   10,801       18,330       62,451       59,673  
Loss from operations   (10,725 )     (18,188 )     (61,885 )     (59,281 )
Other income (expense), net   1,444       2,866       35,452       6,943  
Loss before provision for income taxes   (9,281 )     (15,322 )     (26,433 )     (52,339 )
Provision for income taxes                      
Net loss $ (9,281 )   $ (15,322 )   $ (26,433 )   $ (52,339 )
Net loss per share of Series A preferred stock, basic and diluted $ (128.44 )   $ (212.99 )   $ (366.33 )   $ (728.64 )
Weighted-average Series A preferred stock shares outstanding, basic and diluted   1,250       1,250       1,250       1,250  
Net loss per share of common stock, basic and diluted $ (0.13 )   $ (0.21 )   $ (0.37 )   $ (0.73 )
Weighted-average common stock shares outstanding, basic and diluted   71,009,866       70,687,307       70,905,422       70,580,604  

Select Condensed Consolidated Balance Sheet Data

Unaudited

(in thousands) December 31, 2024   December 31, 2023
Cash, cash equivalents and marketable securities $ 53,075   $ 105,834
Working capital(1)   45,418     98,125
Total assets   92,167     144,027
Total stockholders’ equity   68,226     87,797
(1)Working capital defined as current assets less current liabilities



Contacts

Investor Relations & Media

Victoria Fort
[email protected]



Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects

ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) — Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.

In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on lithium delivery in the brain compared to marketed lithium salts. The study could illuminate the path forward in patients with PTSD by demonstrating AL001’s targeted effectiveness and reduced systemic side effects. Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.

By offering a treatment that potentially eliminates the need for lithium therapeutic drug monitoring (“TDM”), AL001 could revolutionize care for vulnerable patient populations and improve treatment outcomes. Lithium, renowned for its efficacy as a first-line therapy for manic episodes and maintenance in BD, has long been underutilized due to the complexities of TDM. Current lithium salts (carbonate and citrate) approved by the U.S. Food and Drug Administration (“FDA”) are limited by a narrow therapeutic window that requires regular TDM of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events. Although lithium does not have an FDA-approved indication for PTSD, case reports suggest that lithium treatment may be useful for treating PTSD patients. In particular, treatment with low doses (300–600 mg/day) of lithium carbonate have been reported to provide effective treatment in reduction of inappropriate anger, irritability, anxiety, and insomnia in those patients. The clinical observation of mood swings beyond the normal range, but milder than those associated with BD, reportedly suggested the presence of a sub-threshold mood disorder in these PTSD patients. It has also been proposed that treatment of trauma with lithium to forestall the development of PTSD may be provided by pharmacological induction of a mild transient amnesia.

“With AL001, we can potentially introduce a next-generation lithium treatment that offers enhanced safety, better brain targeting, and no need for TDM, promising a leap forward from the current, burdensome options,” stated Stephan Jackman, Chief Executive Officer of Alzamend. “This advancement stands to potentially enhance the lives of over 9 million Americans suffering from PTSD by providing a more effective and user-friendly therapeutic option, potentially reshaping current treatment paradigms and improving patient quality of life substantially.”

About AL001

AL001 is a novel lithium-delivery system that has the potential to provide the benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium. Results from Alzamend’s completed Phase IIA multiple-ascending dose study of AL001 in Alzheimer’s patients and healthy subjects identified a maximum tolerated dose (“MTD”), as assessed by an independent safety review committee. This MTD is designed to be unlikely to require TDM while providing lithium at a relatively modest but effective dose. AL001 is designed to favorably distribute lithium in the brain resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts. This can serve to mitigate or obviate the disadvantageously low ceiling for toxicity of marketed lithium salts that has limited their usefulness to patients and prescribers.

About Alzamend Neuro

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com.


Contacts:


Email: [email protected] or call: 1-844-722-6333

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/6532ebdd-9f8d-4619-8ce1-2dc09c85bca3

https://www.globenewswire.com/NewsRoom/AttachmentNg/cc408d02-4ad2-4b9a-bd66-995ff9004b67

https://www.globenewswire.com/NewsRoom/AttachmentNg/d29a9ec0-9481-4bf9-83d8-d05cccc71a78



X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.

The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the conclusion of the call, a webcast replay will be available on the website.

About X4 Pharmaceuticals

X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

Investor Contact:

Daniel Ferry
Managing Director, LifeSci Advisors
[email protected]
(617) 430-7576

X4 Media Contact:

Rhiannon Jeselonis
Ten Bridge Communications
[email protected]



Core Molding Technologies Reports Full Year and Fourth Quarter 2024 Results

Record Operational Cash Flow and Margin Stability Driven by Strategic Initiatives

COLUMBUS, Ohio, March 11, 2025 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reported financial and operating results for the fiscal periods ended December 31, 2024.

Fiscal Year
2024
Highlights

  • Net sales of $302.4 million, down 15.5% from $357.7 million in the prior year; and product sales of $291.1 million, down 16.2% from the prior year. The decrease in sales is primarily the result of lower demand from customers in all of the Company’s significant markets.
  • Gross margin of $53.3 million, or 17.6% of net sales, compared to $64.5 million or 18.0% of net sales, in the prior year.
  • Selling, general and administrative expenses of $36.6 million, or 12.1% of net sales, compared to $38.0 million or 10.6% of net sales, in the prior year same period.
  • Operating income of $16.7 million, or 5.5% of net sales, versus operating income of $26.5 million, or 7.4% of net sales, in the prior year.
  • Total liquidity at year-end was $91.8 million, net cash provided by operating activities was $35.2 million, free Cash Flow1 was $23.6 million for the year, and the Debt to Trailing Twelve Months Adjusted EBITDA1 was less than 1 times or 0.64 times.
  • Return on Capital Employed (ROCE) was 9.9% and ROCE excluding cash was 13.1% for the year.
  • Net income of $13.3 million, or $1.51 per diluted share, compared to net income of $20.3 million, or $2.31 per diluted share, a year ago. Adjusted net income of $14.3 million, or $1.63 per diluted share, compared to adjusted net income of $20.8 million, or $2.36 per diluted share, in the prior year.
  • Adjusted EBITDA1 of $33.8 million, or 11.2% of net sales, compared to $42.9 million, or 12.0% of net sales, in the prior year.

Fourth
Quarter
2024
Highlights

  • Net sales of $62.5 million, down 15.3% from $73.8 million in the prior year; and product sales of $60.0 million, down 17.1% from the prior year. Sales declined primarily due to lower demand from customers in medium and heavy-duty truck and powersports.
  • Gross margin of $9.9 million, or 15.8% of net sales, compared to $10.9 million or 14.8% of net sales, in the prior year.
  • Selling, general and administrative expenses of $9.0 million, or 14.4% of net sales, compared to $8.4 million or 11.4% of net sales, in the prior year same period.
  • Operating income of $0.9 million, or 1.4% of net sales, versus $2.5 million, or 3.4% of net sales, in the prior year.
  • Net loss of $39 thousand, or $0.00 per diluted share, compared to net income of $2.2 million, or $0.25 per diluted share, a year ago. Adjusted net income of $0.8 million, or $0.10 per diluted share, compared to net income of $2.6 million, or $0.30 per diluted share, in the prior year.
  • Adjusted EBITDA1 of $5.7 million, or 9.2% of net sales, compared to $7.1 million, or 9.6% of net sales in the prior year.

1 Adjusted EBITDA, Free Cash Flow, Adjusted Net Income, Return on Capital Employed Excluding Cash, and Debt to Trailing Twelve Months Adjusted EBITDA are non-GAAP financial measures as defined and reconciled below.

David Duvall, the Company’s President and Chief Executive Officer, said, “Fiscal 2024 was another successful year for the Company in improving our business model and a testament to our work over the last three years to improve and stabilize margins, even with lower sales.   As with all of Core’s successful transformations or Must Win Battles in the last several years, we first optimize the execution process to meet our future vision.   I am pleased with our team’s successful initiatives to improve operational efficiencies, reduce costs, and increase product line profitability in our plants.   This resulted in better stability in our margins and record operational cash flow for Core Molding in 2024 of $35 million.  

“With $45 million of new revenue wins in 2024, we plan to continue ramping our “Invest For Growth” strategy in 2025 as we continue to add resources to our sales & marketing function, now led by our CCO Alex Bantz. We focused on the execution processes with our sales function in 2024 and now we are investing in initiatives to leverage the execution processes into generating sales. Bottom line is that we need to spend more time working directly with our large customers at their locations, helping to solve their problems, and much more time presenting and displaying our capabilities at trade shows. Our three fundamental pillars that support Core’s Must Win Battle this year include 1) Grow Wallet Share by leveraging our relationships with many trusted blue chip customers, 2) Business Diversification and expansion into promising end markets supported by large addressable markets, including Constructions, Industrial, Energy, and Medical where we have seen early successes in 2024, and 3) M&A expansion through one or more strategic acquisitions to drive new sales channels where we have the processes to cross sell, a new geographic footprint advantage, or a process that is complementary to our current processes that grows our wallet share potential.   Our growing sales opportunity pipeline is currently $275 million.”      

John Zimmer, the Company’s EVP and Chief Financial Officer, commented, “The fiscal 2024 demand environment stayed under pressure most of the year and we quickly adjusted costs to match our revenue projections. As we signaled early in 2024, sales were down 15.5%, and we ended the year with net sales of $302.4 million, primarily based on macroeconomic challenges. Our ongoing operational improvements and cost reductions resulted in full year gross margins of 17.6%, even with the loss of fixed cost leverage on lower sales. By maintaining gross margins within our long-term range of 17% to 19% and controlling our sales, general and administrative costs, we were able to generate strong free cash flows of $23.6 million.   

“We are excited about our sales opportunities in 2025. Most of our 2024 new wins will positively impact revenues in 2025, with full production cycles expected in 2026. We also project the truck cycle upturn starting in the second half of 2025, which continues throughout 2026 due to the new regulation changes in 2027. Despite areas of sales growth in 2025, we expect the full year sales to be flat based on the phase-out of approximately $30 million of Volvo programs, offset by higher tooling revenues and new program revenues resulting from new business wins in 2024. Without this Volvo transition, we would have anticipated Core’s sales up about 10% for the year. This demonstrates the early success of our Invest For Growth strategy, which we kicked off in 2024.”

2024
Capital Expenditures

The Company’s capital expenditures for 2024 were $11.5 million, including $2.5 million of capacity and new program investments. The Company plans for 2025 capital expenditures of approximately $10 to $12 million to meet current demand and allow for expansion.

Financial Position at
December 31, 2024

The Company’s total liquidity at the end of 2024 was $91.8 million, with $41.8 million in cash, $25.0 million of undrawn capacity under the Company’s revolving credit facility and $25.0 million of undrawn capacity under the Company’s capex credit facility. The Company’s term debt was $21.5 million at December 31, 2024. The Debt to Trailing Twelve Months Adjusted EBITDA1 was less than one times Adjusted EBITDA1 at the end of the fiscal year.

1Debt to Trailing Twelve Months Adjusted EBITDA, Adjusted EBITDA, Adjusted Net Income, and return on capital employed are metrics and non-GAAP financial measures as defined and reconciled below.
Conference Call

The Company will conduct a conference call today at 10:00 a.m. Eastern Time to discuss financial and operating results for the fiscal year ended December 31, 2024. To access the call live by phone, dial (844) 881-0134 and ask for the Core Molding Technologies call at least 10 minutes prior to the start time. A telephonic replay will be available through March 18, 2025, by calling (877) 344-7529 and using passcode ID: 2691885#. The live webcast of the call will also be available for replay later on the Company’s Investor Relations website at www.coremt.com/investor-relations/events-presentations/.

About Core Molding Technologies, Inc.

Core Molding Technologies is a leading engineered materials company specializing in molded structural products, principally in building products, utilities, transportation and powersports industries across North America. The Company operates in one operating segment as a molder of thermoplastic and thermoset structural products. The Company’s operating segment consists of one reporting unit, Core Molding Technologies. The Company offers customers a wide range of manufacturing processes to fit various program volume and investment requirements. These thermoset processes include compression molding of sheet molding compound (“SMC”), resin transfer molding (“RTM”), liquid molding of dicyclopentadiene (“DCPD”), spray-up and hand-lay-up. The thermoplastic processes include direct long-fiber thermoplastics (“DLFT”) and structural foam and structural web injection molding. Core Molding Technologies serves a wide variety of markets, including the medium and heavy-duty truck, marine, automotive, agriculture, construction, and other commercial products. The demand for Core Molding Technologies’ products is affected by economic conditions in the United States, Mexico, and Canada. Core Molding Technologies’ operations may change proportionately more than revenues from operations.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws that are subject to risks and uncertainties. These statements often include words such as “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions. In particular, this press release may contain forward-looking statements about the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets. Factors that could cause actual results to differ from those reflected in forward-looking statements relating to our operations and business include: dependence on certain major customers, and potential loss of any major customer due to completion of existing production programs or otherwise; general macroeconomic, social, regulatory and political conditions, including uncertainties surrounding volatility in financial markets; changes in the plastics, transportation, marine and commercial product industries (including changes in demand for production), efforts of the Company to expand its customer base and develop new products to diversify markets, materials and processes and increase operational enhancements; the imposition of new or increased tariffs and the resulting consequences; Company’s initiatives to quote and execute manufacturing processes for new business, acquire raw materials, address inflationary pressures, regulatory matters and labor relations; the Company’s financial position or other financial information; and other risks and uncertainties described in the Company’s filings with the SEC. These statements are based on certain assumptions that the Company has made in light of its experience as well as its perspective on historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. Actual results may differ materially from the anticipated results because of certain risks and uncertainties, including those included in the Company’s filings with the SEC. There can be no assurance that statements made in this press release relating to future events will be achieved. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by such cautionary statements.

Company Contact:

Core Molding Technologies, Inc.
John Zimmer
Executive Vice President & Chief Financial Officer
[email protected]

Investor Relations Contact:

Three Part Advisors, LLC
Sandy Martin or Steven Hooser
214-616-2207

– Financial Statements Follow –

Core Molding Technologies, Inc.

Consolidated Statements of Operations

(in thousands, except share and per share data)
 
  Three Months Ended December 31,   Year Ended

December 31,
    2024       2023       2024       2023  
               
Net sales:              
Products $ 60,047     $ 72,439     $ 291,092     $ 347,375  
Tooling   2,451       1,339       11,286       10,363  
Total net sales   62,498       73,778       302,378       357,738  
               
Total cost of sales   52,613       62,841       249,118       293,218  
               
Gross margin   9,885       10,937       53,260       64,520  
               
Selling, general and administrative expense   9,016       8,420       36,565       37,983  
               
Operating income   869       2,517       16,695       26,537  
               
Other (income) and expense              
Interest (income) expense   (94 )     175       (193 )     1,011  
Net periodic post-retirement benefit   (180 )     (63 )     (593 )     (220 )
Total other (income) and expense   (274 )     112       (786 )     791  
               
Income before income taxes   1,143       2,405       17,481       25,746  
               
Income tax (benefit) expense   1,182       223       4,182       5,422  
               
Net (loss) income $ (39 )   $ 2,182     $ 13,299     $ 20,324  
               
Net income per common share:              
Basic $     $ 0.25     $ 1.53     $ 2.37  
Diluted $     $ 0.25     $ 1.51     $ 2.31  
 

Core Molding Technologies, Inc.

Product Sales by Market

(unaudited, in thousands)
 
  Three Months Ended

December 31,
  Year Ended

December 31,
    2024     2023     2024     2023  
Medium and heavy-duty truck $ 34,241   $ 40,626   $ 163,915   $ 181,376  
Power sports   12,220     20,115     68,445     84,688  
Building products   2,689     1,879     17,011     28,743  
Industrial and Utilities   6,347     4,231     18,829     23,658  
All Other   4,550     5,588     22,892     28,910  
Net Product Revenue $ 60,047   $ 72,439   $ 291,092   $ 347,375  
 

Core Molding Technologies, Inc.

Consolidated Balance Sheets

(in thousands)
 
  Year Ended December 31,
    2024       2023  
Assets:      
Current assets:      
Cash and cash equivalents $ 41,803     $ 24,104  
Accounts receivable, net   30,118       41,711  
Inventories, net   18,346       22,063  
Prepaid expenses and other current assets   12,621       15,001  
Total current assets   102,888       102,879  
       
Right of use asset   2,112       3,802  
Property, plant and equipment, net   80,807       81,185  
Goodwill   17,376       17,376  
Intangibles, net   4,430       6,017  
Other non-current assets   1,937       2,118  
Total Assets $ 209,550     $ 213,377  
       
Liabilities and Stockholders’ Equity:      
Liabilities:      
Current liabilities:      
Current portion of long-term debt $ 1,814     $ 1,468  
Accounts payable   17,115       23,958  
Contract liabilities   2,286       5,204  
Compensation and related benefits   7,585       10,498  
Accrued other liabilities   7,911       5,058  
Total current liabilities   36,711       46,186  
       
Other non-current liabilities   2,620       3,759  
Long-term debt   19,706       21,519  
Post retirement benefits liability   3,152       2,960  
Total Liabilities   62,189       74,424  
       
Stockholders’ Equity:      
Common stock   86       86  
Paid in capital   45,760       43,265  
Accumulated other comprehensive income, net of income taxes   2,292       5,301  
Treasury stock   (36,145 )     (31,768 )
Retained earnings   135,368       122,069  
Total Stockholders’ Equity   147,361       138,953  
Total Liabilities and Stockholders’ Equity $ 209,550     $ 213,377  
 

Core Molding Technologies, Inc.

Consolidated Statements of Cash Flows

(in thousands)
 
  Year Ended December 31,
    2024       2023  
Cash flows from operating activities:      
Net income $ 13,299     $ 20,324  
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization   13,399       12,912  
Deferred income tax   473       2,473  
Share-based compensation   2,495       2,923  
Loss on the disposal of assets   241       80  
Losses (Gain) on foreign currency   1,180       (58 )
Change in operating assets and liabilities:      
Accounts receivable   11,593       2,550  
Inventories   3,718       1,808  
Prepaid and other assets   1,673       (5,825 )
Accounts payable   (8,105 )     (4,916 )
Accrued and other liabilities   (3,729 )     3,551  
Post retirement benefits liability   (1,086 )     (980 )
Net cash provided by operating activities   35,151       34,842  
Cash flows from investing activities:      
Purchase of property, plant and equipment   (11,525 )     (9,100 )
Net cash used in investing activities   (11,525 )     (9,100 )
Cash flows from financing activities:      
Gross borrowings on revolving loans         37,098  
Gross repayment on revolving loans         (38,962 )
Payment on principal of term loans   (1,548 )     (1,288 )
Payments for taxes related to net share settlement of equity awards   (1,440 )     (2,669 )
Purchase of common shares   (2,939 )      
Net cash used in financing activities   (5,927 )     (5,821 )
Net change in cash and cash equivalents   17,699       19,921  
Cash and cash equivalents at beginning of year   24,104       4,183  
Cash and cash equivalents at end of year $ 41,803     $ 24,104  
Cash paid for:      
Interest $ 1,074     $ 1,234  
Income taxes $ 2,158     $ 5,250  
Non cash investing activities:      
Fixed asset purchases in accounts payable $ 367     $ 298  
 

Non-GAAP Financial Measures

This press release contains financial information determined by methods other than in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Core Molding management uses non-GAAP measures in its analysis of the Company’s performance. Investors are encouraged to review the reconciliation of non-GAAP financial measures to the comparable GAAP results available in the accompanying tables.

Reconciliation of Non-GAAP Financial Measures

Adjusted EBITDA represents net income before, as applicable from time to time, (i) interest expense, net, (ii) provision (benefit) for income taxes, (iii) depreciation and amortization of long-lived assets, (iv) share based compensation expense, (v) plant closure costs, and (vi) nonrecurring legal settlement costs and associated legal expenses unrelated to the Company’s core operations. Free Cash Flow represents net cash (used in) provided by operating activities less purchase of property, plant and equipment and net working capital. Return on capital employed (ROCE) represents earnings before (i) interest expense, net and (ii) provision (benefit) for income taxes divided by (i) stockholders’ equity and (ii) current and long-term debt. ROCE excluding cash represents ROCE less ending cash balance. These measures have limitations as analytical tools and should not be considered in isolation or as an alternative to performance measure derived in accordance with GAAP as an indicator of our operating performance. We present Adjusted EBITDA, Free Cash Flow, Debt to Trailing Twelve Months Adjusted EBITDA and ROCE because management uses these measures as key performance indicators, and we believe that securities analysts, investors and others use these measures to evaluate companies in our industry. Our calculation of these measures may not be comparable to similarly named measures reported by other companies. The following tables present reconciliations of net income to Adjusted EBITDA, Cash Flow from Operating Activities to Free Cash Flow and Net Income per Share to Adjusted Net Income per Share, the most directly comparable GAAP measures, and ROCE, for the periods presented:

Core Molding Technologies, Inc.

Net (Loss) Income to Adjusted EBITDA Reconciliation

(unaudited, in thousands)
 
  Three months ended December 31,   Twelve Months Ended December 31,
    2024       2023       2024       2023  
Net (loss) income $ (39 )   $ 2,182     $ 13,299     $ 20,324  
Provision for income tax expense   1,182       223       4,182       5,422  
Total other (income) and expenses(1)   (273 )     112       (786 )     791  
Depreciation and amortization   3,362       3,315       13,318       12,831  
Share-based compensation   428       700       2,495       2,923  
Severance Costs   1,066       570       1,294       570  
Adjusted EBITDA $ 5,726     $ 7,102     $ 33,802     $ 42,861  
               
Adjusted EBITDA as a percent of net sales   9.2 %     9.6 %     11.2 %     12.0 %
               

(1)Includes net interest (income) expense, and non-cash periodic post-retirement benefit cost
 

Core Molding Technologies, Inc.

Computation of Debt to Trailing Twelve Months Adjusted EBITDA

(unaudited, in thousands)
 
  Trailing Twelve Month Adjusted EBITDA
Net income $ 13,299  
Provision for income taxes   4,182  
Total other expenses(1)   (786 )
Depreciation and amortization   13,318  
Share-based compensation   2,495  
Severance Costs   1,294  
Adjusted EBITDA $ 33,802  
   
Total Outstanding Term Debt as of December 31, 2024 $ 21,520  
   
Term debt to Trailing Twelve Months Adjusted EBITDA   0.64  
   

(1)Includes net interest (income) expense and non-cash periodic post-retirement benefit cost
 

Core Molding Technologies, Inc.

Computation of Return on Capital Employed

Fiscal Year Ended
December 31, 2024
and
2023

(unaudited, in thousands)
 
    2024       2023  
Equity $ 147,361     $ 138,953  
Structure debt   21,520       22,987  
Total structured investment $ 168,881     $ 161,940  
       
Operating income $ 16,695     $ 26,537  
Return on capital employed   9.9 %     16.4 %
               

Core Molding Technologies, Inc.

Computation of Return on Capital Employed Excluding Cash

Fiscal Year Ended
December 31, 2024
and
2023

(unaudited, in thousands)
 
    2024       2023  
Equity $ 147,361     $ 138,953  
Structure debt   21,520       22,987  
Less Cash $ (41,803 )   $ (24,104 )
Total structured investment, Excluding Cash   127,078       137,836  
       
Operating income $ 16,695     $ 26,537  
Return on capital employed, Excluding Cash   13.1 %     19.3 %
               

Core Molding Technologies, Inc.

Free Cash Flow

Fiscal Year Ended
December 31, 2024
and
2023

(unaudited, in thousands)
 
    2024       2023  
Cash flow provided by operations $ 35,151     $ 34,842  
Purchase of property, plant and equipment   (11,525 )     (9,100 )
Free cash flow surplus $ 23,626     $ 25,742  
 

Core Molding Technologies, Inc.

Adjusted Net (Loss) Income per Share

(unaudited, in thousands)
       
  Three Months Ended
December 31,
  Twelve Months Ended
December 31,
    2024       2023     2024     2023  
Net (Loss) Income $ (39 )   $ 2,182   $ 13,299   $ 20,324  
Severance Costs (net of tax) $ 842     $ 450   $ 1,022   $ 450  
Adjusted net income $ 803     $ 2,632   $ 14,321   $ 20,774  
               
Weighted average common shares outstanding – basic   8,644,000       8,653,000     8,693,000     8,550,000  
Weighted average common and potentially issuable common shares outstanding- diluted   8,720,000       8,878,000     8,787,000     8,772,000  
               
Net (loss) income per share – basic $     $ 0.25   $ 1.53   $ 2.37  
Severance Costs (net of tax)   0.10       0.05     0.12     0.05  
Adjusted net income per share – basic $ 0.10     $ 0.30   $ 1.65   $ 2.42  
               
Net (loss) income per share – diluted $     $ 0.25   $ 1.51   $ 2.31  
Severance Costs (net of tax)   0.10       0.05     0.12     0.05  
Adjusted net income per share – diluted $ 0.10     $ 0.30   $ 1.63   $ 2.36  



Advent Technologies and the European Climate, Infrastructure and Environment Executive Agency (CINEA) Sign €34.5 Million EU Innovation Fund Grant Agreement

LIVERMORE, Calif. and ATHENS, Greece, March 11, 2025 (GLOBE NEWSWIRE) — Advent Technologies Holdings, Inc. (NASDAQ: ADN) (“Advent “or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, is pleased to announce that the European Climate, Infrastructure and Environment Executive Agency (CINEA) and Advent’s wholly owned Greek subsidiary, Advanced Energy Technologies S.A. have each signed the grant agreement for the Company’s monumental RHyno Project. This EU Innovation Fund grant will provide Advent with €34,534,318 in non-dilutive funding over the lifetime of the project, with funding to be received incrementally contingent upon completion of certain performance milestones.

Dr. Nora Gourdoupi, Senior Vice President, Corporate Business Development and leader of the RHyno project commented “I am very proud of our team, and especially Dr. Olga Bereketidou, who demonstrated strong commitment in getting this project over the finish line. We met all the technical challenges head on and laid out a realistic and manageable road map for the completion of this project. The RHyno project is a big win for everyone at Advent, and it will certainly be a big win for Kozani, the Region of Western Macedonia, and the country of Greece.”

Jim Coffey, Advent’s Chief Operating Officer added “The RHyno project will be transformative. It is the result of many years of hard work and dedication put in by our teams in Patras, Kozani, and Athens, Greece. The project positions the Company extremely well for the development of strong industrial partnerships, collaborations with top academic institutions, and validates our recent outreach efforts to municipal and government leaders in Kozani and Athens.”

Gary Herman, Chief Executive Officer stated, “Everyone on the team worked very hard for this achievement. Advent had the highest ranking amongst all the 337 proposals submitted in the Innovation Fund 2023 Call from across Europe. We thank our Advent colleagues, and especially our advisor on this project, PwC Greece (PwC) and its responsible engagement leader, Mr. Iannis Voutsinos We would also like to thank the collaborative efforts of Mr. Ioannis Kaltsas, Head of Division at the European Investment Bank, and Mr. Georgios Amanatides, the Regional Governor of Western Macedonia who were instrumental and contributed to our success.

About RHyno Project

The Advent Renewable Hydrogen Innovative Technologies (RHyno) project involves the establishment of infrastructure for developing innovative fuel cells, electrolysers, and their key components including Advent ground-breaking Membrane Electrode Assembly technology at a megawatt (MW) scale. RHyno aims to pioneer the use of innovative materials to enhance power density and lifespan while significantly reducing the weight and volume of power systems through a streamlined balance of plant.

The state-of-the-art facility is designed to optimize production processes, boost efficiency, and industrialize fuel cell and electrolyser technologies. These advancements are essential for decarbonizing carbon intense industries, such as the aviation, maritime and heavy-duty automotive sectors, with further potential for spillover to other sectors, positioning Advent at the forefront of the clean energy transition.

About the EU Innovation Fund

The EU Innovation Fund is one of the world’s largest funding programmes for the commercial demonstration of innovative low-carbon technologies, aiming to bring to market industrial solutions to decarbonize Europe and support its transition to climate neutrality. Among the wide range of financial instruments available on the EU level, it plays a unique role due to its size and focus on the last steps in the rollout of innovative clean tech.

About Advent Technologies Holdings, Inc.

Advent Technologies Holdings, Inc. is a U.S. corporation operating in the fuel cell, methanol, and hydrogen technology sector. Advent focuses on developing and manufacturing the Membrane Electrode Assembly (MEA) and the fuel cell stack, the most critical component of the fuel cell system. Advent is headquartered in Livermore, CA, with offices in Athens and Patras, Greece. The Company holds approximately 150 patents related to HT-PEM fuel cell technology. Advent’s fuel cells enable the use of green eFuels (eMethanol), renewable natural gas, or hydrogen on board. The HT-PEM fuel cells are highly efficient in terms of thermal management and highly resilient under extreme environmental conditions, offering an “Any Fuel. Anywhere.” platform. Applications include stationary, portable, data center, off-grid power generation markets, and heavy-duty mobility (automotive, aviation, marine).  

For more information, visit www.advent.energy.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to maintain the listing of the Company’s common stock on Nasdaq; future financial performance; public securities’ potential liquidity and trading; impact from the outcome of any known and unknown litigation; ability to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; expectations regarding future expenditures; future mix of revenue and effect on gross margins; attraction and retention of qualified directors, officers, employees and key personnel; ability to compete effectively in a competitive industry; ability to protect and enhance Advent’s corporate reputation and brand; expectations concerning its relationships and actions with technology partners and other third parties; impact from future regulatory, judicial and legislative changes to the industry; ability to locate and acquire complementary technologies or services and integrate those into the Company’s business; future arrangements with, or investments in, other entities or associations; and intense competition and competitive pressure from other companies worldwide in the industries in which the Company will operate; and the risks identified under the heading “Risk Factors” in Advent’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on August 13, 2024, as well as the other information filed with the SEC. Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read Advent’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. Advent’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should consider these risks and uncertainties.

Contacts

Advent Technologies Holdings, Inc.
[email protected]



PDS Biotech Leadership to Participate in March Conferences

PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.

Details of the presentations are as follows:

Zacks SCR Life Sciences Virtual Investor Forum

Date: Thursday, March 13, 2025
Event: Investor Presentation
Time: 2:30 p.m. PM ET
Registration: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/4894272/pds-biotechnology-corporation-nasdaq-pdsb

2025 CAGLA NeauxCancer Conference

Date: Friday, March 28, 2025
Event: Scientific Presentation
Session: Innovation Track
Time: 4:00 p.m. PM ET
Location: The Roosevelt, New Orleans
Registration: To live stream the event, click here. For virtual registration, click the link below then select “Investor” in the “Registration Type” dropdown menu: https://web.cvent.com/event/d39429d9-aa77-42d9-9527-e1933ab84f19/regProcessStep1

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune® HPV, PDS01ADC and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, PDS01ADC and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Versamune® is a registered trademark of PDS Biotechnology Corporation.

Investor Contact:

Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: [email protected]

Media Contact:

Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: [email protected]



YY Group Holding Limited’s First Overseas Market to Achieve Rapid Growth, YY Circle Malaysia, Secures Six Deals, Expanding Revenue Pipeline to US$13 Million for 2025

Singapore, March 11, 2025 (GLOBE NEWSWIRE) — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group”, “YYGH”, or the “Company”) is pleased to announce that YY Circle Malaysia, a subsidiary of YY Group, has successfully signed six new strategic deals in Malaysia since January 2025. This achievement highlights YY Circle’s commitment to delivering innovative solutions and building strong partnerships in the hospitality and staffing sectors.

The newly secured partnerships include prominent hotel brands such as Four Points by Sheraton and Hyatt, with operations already commenced at the start of this month. Additionally, Holiday Inn and Marriott Resort & Spa are set to launch their collaborations with YY Circle in April 2025, further solidifying the company’s footprint in the hospitality sector.

These partnerships bring YY Circle Malaysia’s annual revenue pipeline to an impressive US$13 million, marking significant growth in its third year in Malaysia. This upward trajectory underscores promising prospects for YY Circle’s planned overseas expansion and reinforces its position as a leader in the on-demand staffing industry.

Building Strong Partnerships

The new deals underscore YY Circle’s growing influence among international hotel chains. By partnering with globally recognized brands, the company strengthens its foothold in the Malaysian market while laying the foundation for expansion into new markets.

A Promising Future

“These partnerships mark a significant milestone in our journey of growth and innovation,” said Mike Fu, Chief Executive Officer and Executive Director of YY Group Holding Limited. “We are excited to collaborate with these esteemed clients and are committed to delivering exceptional value that supports their operational excellence and success.”

YY Circle Malaysia’s Country Manager, Ken Teng is equally thrilled for the potential that he sees in the Malaysian market, stating, “Having established a strong presence in hospitality, we’re now excited to expand into other sectors like cleaning and retail, unlocking new opportunities for growth.”

With its innovative solutions, YY Circle Malaysia continues to demonstrate its ability to meet the evolving needs of the clients, and drive value for its partners.

About YY Circle:

YY Circle Malaysia, a subsidiary of YY Group Holding Limited, is a leading provider of on-demand staffing solutions and hotel management systems. With a focus on innovation and partnership, YY Circle is committed to empowering businesses in the hospitality industry to achieve their operational goals seamlessly.

About YY Holdings Limited:

YY Group Holding Limited is a Singapore-based data and technology-driven company that specializes in creating enterprise intelligent labor matching services and smart cleaning solutions. Rooted in innovation and a commitment to user-centric experiences, YY Circle leverages app-based technology to optimize the labor sourcing market and the Internet of Things to revolutionize the cleaning industry.

For more information on the Company, please log on to https://yygroupholding.com/.

Investor Contact

Phua Zhi Yong, Chief Financial Officer
YY Group
[email protected]

Mark Wendou Niu, Chief Strategy Officer
YY Group
[email protected]